Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Biogen’s Aduhelm Savings Spur Medicare Call for Lower Premiums

May 27, 2022, 9:17 PM

The Biden administration says the Medicare “Part B” outpatient premium for 2023 should be reduced to reflect “lower-than-expected” spending on Biogen Inc.'s Alzheimer’s drug.

A report issued Friday by the Centers for Medicare & Medicaid Services recommended the premium rate adjustment for Part B coverage. It follows calls for the administration to reduce the program’s largest-ever rate increase in 2022, after Biogen lowered the price of Aduhelm and Medicare decided to limit coverage to patients enrolled in certain clinical trials.

“Given the information available today, it is expected that the 2023 premium will be lower than 2022. The final determination ...